Skip to main
SCLX
SCLX logo

SCLX Stock Forecast & Price Target

SCLX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scilex Holding Co. is positioned favorably due to its ability to secure diversified revenue streams through strategic partnerships, which enhances its financial stability and supports ongoing research and development initiatives. The promising therapeutic profile of SP-102, characterized by its rapid onset and sustained efficacy, alongside a strong safety profile, distinguishes it in the market for pain management solutions. Additionally, the anticipated approval of ELYXYB® in Canada in early 2025 reinforces the company's growth potential, driven by its proprietary technology and strategic legal protections for its product pipeline.

Bears say

Scilex Holding Co's stock outlook appears negative due to a combination of market caution, which has led to a lower overall valuation, and investor sensitivity to broader financial conditions that adversely affect biotech companies. The company's connection to Sorrento Therapeutics raises concern, as Sorrento's own financial difficulties and liquidity issues may hinder Scilex's ability to establish itself as a standalone entity. Furthermore, the application of a 30% discount rate in valuation models reflects skepticism regarding Scilex's clinical pipeline and product commercialization prospects, compounding the factors contributing to its distressed valuation.

SCLX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scilex Holding Co and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scilex Holding Co (SCLX) Forecast

Analysts have given SCLX a Strong Buy based on their latest research and market trends.

According to 5 analysts, SCLX has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scilex Holding Co (SCLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.